ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
Clinical trials for ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise for Tough-to-Treat breast cancer
Disease control OngoingThis phase 3 trial tests whether adding the drug palbociclib to standard anti-HER2 and hormone therapy can help people with a specific type of advanced breast cancer (HR+/HER2+) live longer without their disease getting worse. About 518 participants will receive either the triple…
Matched conditions: ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE3 • Sponsor: Alliance Foundation Trials, LLC. • Aim: Disease control
Last updated May 16, 2026 23:53 UTC
-
New combo aims to stall advanced breast cancer
Disease control OngoingThis study tests whether adding an experimental drug (AZD5363) to standard hormone therapy (fulvestrant) can help control advanced breast cancer in postmenopausal women. About 150 women whose cancer worsened on previous hormone therapy will receive either the combo or a placebo. …
Matched conditions: ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Velindre NHS Trust • Aim: Disease control
Last updated May 16, 2026 23:46 UTC
-
New hope for breast cancer: which hormone treatment shrinks tumors best before surgery?
Disease control OngoingThis phase 3 study tests whether giving a combination of two hormone-blocking drugs (fulvestrant and anastrozole) or fulvestrant alone before surgery works better than the standard anastrozole alone for shrinking estrogen receptor-positive breast cancer in postmenopausal women. A…
Matched conditions: ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Immune booster before chemo shows promise for tough breast cancers
Disease control OngoingThis study tests whether giving two immunotherapy drugs (decitabine and pembrolizumab) before standard chemotherapy can increase immune cell activity in breast tumors. It involves 46 people with locally advanced HER2-negative breast cancer, divided by hormone receptor status. The…
Matched conditions: ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated May 11, 2026 20:47 UTC
-
Can a simple moisturizer beat estrogen for vaginal dryness in breast cancer survivors?
Symptom relief OngoingThis study looks at two treatments—vaginal estrogen and a moisturizer called Replens—for vaginal dryness in breast cancer patients taking aromatase inhibitors. About 33 women with estrogen-receptor-positive breast cancer will be followed for 6 months to see which treatment works …
Matched conditions: ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Polly A. Niravath, MD • Aim: Symptom relief
Last updated May 04, 2026 16:19 UTC
-
Blood tests may reduce unnecessary scans for metastatic breast cancer patients
Knowledge-focused OngoingThis study looks at whether simple blood tests can predict when a patient's cancer is stable, so they can skip some routine scans. About 97 women with ER-positive, HER2-negative metastatic breast cancer taking hormone therapy will give blood samples at regular checkups. Researche…
Matched conditions: ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
Sponsor: The Christie NHS Foundation Trust • Aim: Knowledge-focused
Last updated May 16, 2026 23:48 UTC
-
Can a PET scan predict bone cancer treatment success?
Knowledge-focused OngoingThis study looks at whether a special PET scan can help doctors see how well hormone therapy is working in breast cancer that has spread to the bones. About 75 adults with ER+ breast cancer and bone metastases will get a PET scan before starting new hormone treatment, then again …
Matched conditions: ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated May 11, 2026 20:53 UTC